Allogene Therapeutics, Inc. Variable Lease, Cost
Allogene Therapeutics, Inc. (ALLO) reported Variable Lease, Cost of $769.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-12
- Allogene Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $769.00K, a 60.88% increase year-over-year.
- Allogene Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $601.00K, a 8.09% increase year-over-year.
- Allogene Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $770.00K, a 14.06% decline year-over-year.
- Allogene Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $703.00K, a 15.71% decline year-over-year.
- Allogene Therapeutics, Inc. variable lease, cost for fiscal 2025 was $2.51M, a 19.26% decline from fiscal 2024.
- Allogene Therapeutics, Inc. variable lease, cost for fiscal 2024 was $3.10M, a 0.10% increase from fiscal 2023.
- Allogene Therapeutics, Inc. variable lease, cost for fiscal 2023 was $3.10M, a 45.02% increase from fiscal 2022.
- Allogene Therapeutics, Inc. variable lease, cost for fiscal 2022 was $2.14M, a 31.31% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $769.00K 10-Q · filed 2026-08-12 | $1.37M 10-Q · filed 2026-08-12 | $2.14M derived: sum of 3 quarters · filed 2026-08-12 | $2.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $601.00K 10-Q · filed 2026-05-13 | $1.37M derived: sum of 2 quarters · filed 2026-05-13 | $2.07M derived: sum of 3 quarters · filed 2026-05-13 | $2.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.47M derived: sum of 2 quarters · filed 2026-03-12 | $1.95M derived: sum of 3 quarters · filed 2026-08-12 | $2.51M 10-K · filed 2026-03-12 |
| 2025-09-30 | $703.00K 10-Q · filed 2025-11-06 | $1.18M derived: sum of 2 quarters · filed 2026-08-12 | $1.74M 10-Q · filed 2025-11-06 | $2.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $478.00K 10-Q · filed 2026-08-12 | $1.03M 10-Q · filed 2026-08-12 | $1.93M derived: sum of 3 quarters · filed 2026-08-12 | $2.76M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $556.00K 10-Q · filed 2026-05-13 | $1.45M derived: sum of 2 quarters · filed 2026-05-13 | $2.29M derived: sum of 3 quarters · filed 2026-05-13 | $2.79M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.73M derived: sum of 2 quarters · filed 2026-03-12 | $2.24M derived: sum of 3 quarters · filed 2026-03-12 | $3.10M 10-K · filed 2026-03-12 |
| 2024-09-30 | $834.00K 10-Q · filed 2025-11-06 | $1.34M derived: sum of 2 quarters · filed 2025-11-06 | $2.21M 10-Q · filed 2025-11-06 | $3.36M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $508.00K 10-Q · filed 2025-08-13 | $1.38M 10-Q · filed 2025-08-13 | $2.53M derived: sum of 3 quarters · filed 2025-08-13 | $3.11M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $867.00K 10-Q · filed 2025-05-13 | $2.02M derived: sum of 2 quarters · filed 2025-05-13 | $2.61M derived: sum of 3 quarters · filed 2025-05-13 | $3.28M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.74M derived: sum of 2 quarters · filed 2025-03-13 | $2.41M derived: sum of 3 quarters · filed 2025-03-13 | $3.10M 10-K · filed 2025-03-13 |
| 2023-09-30 | $587.00K 10-Q · filed 2024-11-07 | $1.26M derived: sum of 2 quarters · filed 2024-11-07 | $1.95M 10-Q · filed 2024-11-07 | $2.62M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $672.00K 10-Q · filed 2024-08-07 | $1.36M 10-Q · filed 2024-08-07 | $2.03M derived: sum of 3 quarters · filed 2024-08-07 | $2.65M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $691.00K 10-Q · filed 2024-05-13 | $1.36M derived: sum of 2 quarters · filed 2024-05-13 | $1.98M derived: sum of 3 quarters · filed 2024-05-13 | $2.38M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $671.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $1.29M derived: sum of 2 quarters · filed 2024-03-14 | $1.68M derived: sum of 3 quarters · filed 2024-03-14 | $2.14M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $616.00K 10-Q · filed 2023-11-02 | $1.01M derived: sum of 2 quarters · filed 2023-11-02 | $1.47M 10-Q · filed 2023-11-02 | $2.12M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $397.00K 10-Q · filed 2023-08-02 | $852.00K 10-Q · filed 2023-08-02 | $1.50M derived: sum of 3 quarters · filed 2024-03-14 | $1.95M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $455.00K 10-Q · filed 2023-05-03 | $1.10M derived: sum of 2 quarters · filed 2024-03-14 | $1.55M derived: sum of 3 quarters · filed 2024-03-14 | $1.76M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $650.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $1.10M derived: sum of 2 quarters · filed 2024-03-14 | $1.30M derived: sum of 3 quarters · filed 2024-03-14 | $1.63M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $448.00K 10-Q · filed 2022-11-02 | $652.00K derived: sum of 2 quarters · filed 2022-11-02 | $979.00K 10-Q · filed 2022-11-02 | $1.40M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-06-30 | $204.00K 10-Q · filed 2022-08-09 | $531.00K 10-Q · filed 2022-08-09 | $952.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.30M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-03-31 | $327.00K 10-Q · filed 2022-05-04 | $748.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.10M derived: sum of 3 quarters · filed 2024-03-14 | $1.50M derived: sum of 4 quarters · filed 2024-03-14 |
| 2020-12-31 | $421.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $774.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.17M derived: sum of 3 quarters · filed 2024-03-14 | $1.38M 10-K/A · filed 2024-03-14 |
| 2020-09-30 | $353.00K 10-Q · filed 2021-11-04 | $752.00K derived: sum of 2 quarters · filed 2021-11-04 | $961.00K 10-Q · filed 2021-11-04 | $1.35M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $399.00K 10-Q · filed 2021-08-04 | $608.00K 10-Q · filed 2021-08-04 | $994.00K derived: sum of 3 quarters · filed 2022-02-23 | $1.27M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $210.00K 10-Q · filed 2021-05-05 | $595.00K derived: sum of 2 quarters · filed 2022-02-23 | $872.00K derived: sum of 3 quarters · filed 2022-02-23 | $1.14M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $385.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $662.00K derived: sum of 2 quarters · filed 2022-02-23 | $925.00K derived: sum of 3 quarters · filed 2022-02-23 | $1.09M 10-K · filed 2022-02-23 |
| 2019-09-30 | $277.00K 10-Q · filed 2020-11-04 | $540.00K derived: sum of 2 quarters · filed 2020-11-04 | $702.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $263.00K 10-Q · filed 2020-08-05 | $401.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $139.00K 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $32.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |